Adverse effect versus quality control of the Fuenzalida-Palacios antirabies vaccine

Rev Inst Med Trop Sao Paulo. 1998 Sep-Oct;40(5):295-9. doi: 10.1590/s0036-46651998000500006.


We evaluated the components of the Fuenzalida-Palacios antirabies vaccine, which is till used in most developing countries in human immunization for treatment and prophylaxis. This vaccine is prepared from newborn mouse brains at 1% concentration. Even though the vaccine is considered to have a low myelin content, it is not fully free of myelin or of other undesirable components that might trigger adverse effects after vaccination. The most severe effect is a post-vaccination neuroparalytic accident associated with Guillain-Barré syndrome. In the present study we demonstrate how the vaccines produced and distributed by different laboratories show different component patterns with different degrees of impurity and with varying protein concentrations, indicating that production processes can vary from one laboratory to another. These differences, which could be resolved using a better quality control process, may affect and impair immunization, with consequent risks and adverse effects after vaccination. We used crossed immunoelectrophoresis to evaluate and demonstrate the possibility of quality control in vaccine production, reducing the risk factors possibly involved in these immunizing products.

MeSH terms

  • Cell Culture Techniques
  • Proteins / analysis*
  • Quality Control
  • Rabies Vaccines / adverse effects*
  • Rabies Vaccines / chemistry
  • Serum Albumin / analysis


  • Proteins
  • Rabies Vaccines
  • Serum Albumin